TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21565921

Group type: EXPERIMENTAL
Intervention: Nicotine-free inhalator group (PAIPO)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 120
Study: 19360477

Group type: EXPERIMENTAL
Intervention: Dorsal Tactile Display (DTD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Belt Tactile Display (TB)
Number of subjects: 24
Study: 16720537

Group type: EXPERIMENTAL
Intervention: General and tailored CRC risk factor feedback (absolute risk group)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Absolute CRC risk factor feedback plus CRC feedback as to how their total number of risk factors compared with that of others (absolute plus comparative risk group)
Number of subjects: 160

Group type: COMPARATOR
Intervention: General CRC risk factors (control)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Participants informed they were at lower comparative risk
Number of subjects: 160
Study: 15228966

Group type: EXPERIMENTAL
Intervention: Nicotrol nicotine inhaler (OTC)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Nicotrol nicotine inhaler (HCP)
Number of subjects: 520
Study: 11325322

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant medication (amitriptyline hydrochloride, up to 100 mg/d, or nortriptyline hydrochloride, up to 75 mg/d)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Stress management therapy (3 sessions and 2 telephone contacts) plus placebo
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Stress management therapy plus antidepressant medication
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 9513669

Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam 40 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1884268

Group type: EXPERIMENTAL
Intervention: Peroperative and post-ECC transfusion of blood removed after induction of anaesthesia (Group I)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Postoperative transfusion of extravasated thoracic blood (Group II)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combination of peroperative and postoperative transfusion (Group III)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 74
Study: 6411615

Group type: EXPERIMENTAL
Intervention: Intravenous fat tolerance test
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Infused fat during 24 hours
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Energy expenditure and nitrogen balance
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate oxidation
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition with fat dosage of 2.5 g/kg X d‐1
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 10
Study: 31818053

Group type: EXPERIMENTAL
Intervention: Musculoskeletal ultrasonography (MSUS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sports medicine physician (SMP)
Number of subjects: 0
Study: 31386203

Group type: EXPERIMENTAL
Intervention: on‐BEAM intervention (personalized normative feedback and motivational interviewing techniques)
Number of subjects: 1496

Group type: EXPERIMENTAL
Intervention: on‐BEAM intervention
Number of subjects: 1496

Group type: COMPARATOR
Intervention: Control group (assessment and results without normative feedback)
Number of subjects: 1496
Study: 28323797

Group type: EXPERIMENTAL
Intervention: Local vancomycin powder (up to a maximum dose of 1000 mg, placed immediately before wound closure)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 500
Study: 27475691

Group type: EXPERIMENTAL
Intervention: Fentanyl Transdermal System (FTS)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (placebo patch and analgesic)
Number of subjects: 17
Study: 24011845

Group type: EXPERIMENTAL
Intervention: Protocol group (managed pharmacologically according to the protocol)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (managed according to ICU routine)
Number of subjects: 201
Study: 21037490

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid, 2 g/d)
Number of subjects: 20
Study: 20110013

Group type: EXPERIMENTAL
Intervention: Test formulation of rebamipide 100 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Reference formulation of rebamipide 100 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 30
Study: 17203281

Group type: EXPERIMENTAL
Intervention: 20% sucrose
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 20% glucose
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 31
Study: 15271730

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Affected side
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control side
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Change in VNRS score
Number of subjects: 20
Study: 11234938

Group type: EXPERIMENTAL
Intervention: Hands of diabetic patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Feet of diabetic patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetics
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Non-insulin-dependent diabetics
Number of subjects: 100
Study: 10225575

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (100 mg bd for 3 days)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Co-trimoxazole (160/800 mg bd for 7 days)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Nitrofurantoin (100 mg bd for 7 days)
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 713

Group type: COMPARATOR
Intervention: Co-trimoxazole
Number of subjects: 713
Study: 8059818

Group type: EXPERIMENTAL
Intervention: Monophasic combination of 30 micrograms ethinyl estradiol and 75 micrograms gestodene (treatment group, n = 12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nonhormonal contraception (control group, n = 13)
Number of subjects: 25
Study: 2741619

Group type: EXPERIMENTAL
Intervention: Continuous glucose-saline infusion
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5-hour glucose infusion
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standardized intravenous fluids
Number of subjects: 2
Study: 4595181

Group type: EXPERIMENTAL
Intervention: diazepam (Valium)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: propranolol (Inderal)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 29908804

Group type: EXPERIMENTAL
Intervention: Automatic milking system (AMS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tandem milking (Control)
Number of subjects: 90
Study: 26799528

Group type: EXPERIMENTAL
Intervention: Bone-level implants with mucosal thickness ≤2 mm (Group A, MC)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Bone-level implants with mucosal thickness >2 mm (Group B, MC)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tissue-level implants with mucosal thickness ≤2 mm (Group A, LC)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Tissue-level implants with mucosal thickness >2 mm (Group B, LC)
Number of subjects: 33
Study: 25727892

Group type: EXPERIMENTAL
Intervention: Alkalosis (ALK; 0.3 g (kg body weight)(-1) sodium bicarbonate)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (PLA; 0.3 g (kg body weight)(-1) calcium carbonate)
Number of subjects: 11
Study: 23531267

Group type: EXPERIMENTAL
Intervention: Negative peer influence (unsafe decisions)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Positive peer influence (cautious decisions)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Silent peer (no influence)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No peer (completed task alone)
Number of subjects: 80
Study: 21998287

Group type: EXPERIMENTAL
Intervention: Treatment for early syphilis
Number of subjects: 465
Study: 18293426

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) as part of local treatment
Number of subjects: 553
Study: 16595098

Group type: EXPERIMENTAL
Intervention: Brief counselling plus nursing follow-up
Number of subjects: 125

Group type: COMPARATOR
Intervention: Brief counselling from the doctor (control group)
Number of subjects: 125
Study: 12533330

Group type: EXPERIMENTAL
Intervention: 20 mg glatiramer acetate (GA)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 10894863

Group type: EXPERIMENTAL
Intervention: Etoposide, leucovorin, and bolus fluorouracil (ELF)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Infusional fluorouracil plus cisplatin (FUP)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Fluorouracil, doxorubicin, and methotrexate (FAMTX)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Toxicity
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Treatment-related deaths
Number of subjects: 399
Study: 9184261

Group type: EXPERIMENTAL
Intervention: Calcium salts (specific types not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium citrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium gluconolactate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ossein-hydroxyapatite complex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study: 8300824

Group type: EXPERIMENTAL
Intervention: Glutathione therapy (600 mg i.m. injection every other day for 2 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (equal volume of a placebo preparation for 2 months)
Number of subjects: 20
Study: 3814032

Group type: EXPERIMENTAL
Intervention: Atropine (4 mg X 70 kg‐1 body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2-PAM chloride (up to 1200 mg X 70 kg‐1 body weight)
Number of subjects: 0
Study: 28803744

Group type: EXPERIMENTAL
Intervention: NER1006
Number of subjects: 621

Group type: COMPARATOR
Intervention: trisulfate
Number of subjects: 621
Study: 27938540

Group type: EXPERIMENTAL
Intervention: H2∶O2 mixture (66.67%∶33.33%) inhalation for 1 hour per day for 30 days
Number of subjects: 96

Group type: COMPARATOR
Intervention: N2∶O2 mixture (66.67%∶33.33%) inhalation for 1 hour per day for 30 days
Number of subjects: 96
Study: 24955451

Group type: EXPERIMENTAL
Intervention: 2-L polyethylene glycol + ascorbic acid (PEG + Asc)
Number of subjects: 327

Group type: COMPARATOR
Intervention: 4-L polyethylene glycol (4-L PEG)
Number of subjects: 327
Study: 24343290

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 21506146

Group type: EXPERIMENTAL
Intervention: 60 Hz STN DBS
Number of subjects: 11

Group type: COMPARATOR
Intervention: 130 Hz STN DBS
Number of subjects: 11

Group type: COMPARATOR
Intervention: defined Off
Number of subjects: 11
Study: 18436114

Group type: EXPERIMENTAL
Intervention: Darapladib 40 mg
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Darapladib 80 mg
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Darapladib 160 mg
Number of subjects: 959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959
Study: 16573804

Group type: EXPERIMENTAL
Intervention: Eudragit-L-coated mesalazine tablets
Number of subjects: 215

Group type: COMPARATOR
Intervention: Ethylcellulose-coated mesalazine tablets
Number of subjects: 215
Study: 12679312

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 60 mg BID
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 90 mg BID
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 60 mg thrice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 90 mg thrice daily
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dextromethorphan 120 to 270 mg/day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10743870

Group type: EXPERIMENTAL
Intervention: Sadness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anger
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotion-specific bias
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive effort
Number of subjects: 0
Study: 9013088

Group type: EXPERIMENTAL
Intervention: E2/NETA (continuous oral 17 beta‐oestradiol 2 mg day‐1 and norethisterone acetate 1 mg day‐1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: E2/MPA (transdermal 17 beta‐oestradiol 50 micrograms day‐1 with oral cyclic medroxyprogesterone acetate 10 mg day‐1 on days 17-28)
Number of subjects: 75
Study: 1524955

Group type: EXPERIMENTAL
Intervention: Bestatin (30 mg orally daily for three months after molar deliveries)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Bestatin non-administered group
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Bestatin
Number of subjects: 49
Study: 3883421

Group type: EXPERIMENTAL
Intervention: Meglumine/sodium diatrizoate (60%)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hexabrix (new monoacidic dimer)
Number of subjects: 31
Study: 31471444

Group type: EXPERIMENTAL
Intervention: Taiji exercise for 10 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Aerobic exercise for 10 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Taiji exercise and Aerobic exercise
Number of subjects: 80
Study: 29227294

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (EXE: arm crank ergometer, 30 min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control session (CON: participants remained seated on the cycle ergometer, 30 min)
Number of subjects: 9
Study: 26764063

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with a self-expanding prosthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study: 24751369

Group type: EXPERIMENTAL
Intervention: High-sense-of-control
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Low-sense-of-control
Number of subjects: 106

Group type: COMPARATOR
Intervention: No-intervention
Number of subjects: 106
Study: 23689969

Group type: EXPERIMENTAL
Intervention: Neydharting mud-pack therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (hot packs)
Number of subjects: 53
Study: 20219528

Group type: EXPERIMENTAL
Intervention: Active commuting (defined as engaging in physical activity during commuting)
Number of subjects: 7280

Group type: EXPERIMENTAL
Intervention: Time spent on walking or cycling during commuting
Number of subjects: 7280

Group type: EXPERIMENTAL
Intervention: Socio-demographic factors (residency, education, income, occupational PA)
Number of subjects: 7280

Group type: EXPERIMENTAL
Intervention: Smoking and leisure-time physical activity
Number of subjects: 7280
Study: 18201563

Group type: EXPERIMENTAL
Intervention: 40 mg pravastatin/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 10 mg pravastatin/day
Number of subjects: 40
Study: 15844022

Group type: EXPERIMENTAL
Intervention: Nasobiliary drain (NBD)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Stent placement
Number of subjects: 150
Study: 12757964

Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10484842

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (accelerated radiotherapy, 20 Gy in 5 fractions)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 123
Study: 8554936

Group type: EXPERIMENTAL
Intervention: (S)-flurbiprofen (50 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: (R)-flurbiprofen (50 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: (R)-flurbiprofen (100 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2111665

Group type: EXPERIMENTAL
Intervention: Anisoylated plasminogen streptokinase activator complex (APSAC): 30 IU in 5 minutes
Number of subjects: 231

Group type: COMPARATOR
Intervention: Heparin therapy (5,000 IU)
Number of subjects: 231
Study: 646300

Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study: 31092252

Group type: EXPERIMENTAL
Intervention: Elements virtual rehabilitation (three weekly 30-40 min sessions for four weeks) combined with treatment as usual
Number of subjects: 21

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 21
Study: 28049742

Group type: EXPERIMENTAL
Intervention: Mid-frequency ventilation (up to 150 breaths/min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional ventilation (≤60 breaths/min)
Number of subjects: 12
Study: 24786228

Group type: EXPERIMENTAL
Intervention: Home Blood Pressure (HBP) measurements
Number of subjects: 400

Group type: COMPARATOR
Intervention: Clinic Blood Pressure (CBP) measurements
Number of subjects: 400
Study: 23392747

Group type: EXPERIMENTAL
Intervention: HCl (0.1 N) infusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 16
Study: 20385397

Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 119

Group type: COMPARATOR
Intervention: ABC
Number of subjects: 119
Study: 18804988

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 0
Study: 16686762

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Cyclosporine (CyA)
Number of subjects: 314
Study: 14747672

Group type: EXPERIMENTAL
Intervention: IMCI-derived nutrition counseling protocol training for physicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group without continuing education in nutrition
Number of subjects: 0
Study: 11098966

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition enriched with arginine and glutamate (GlnP+ group)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional total parenteral nutrition (control group)
Number of subjects: 15
Study: 9203170

Group type: EXPERIMENTAL
Intervention: Citicoline 1000 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Citicoline 500 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Citicoline 300 mg/day + Nimodipine 90 mg/day
Number of subjects: 24
Study: 8315428

Group type: EXPERIMENTAL
Intervention: PCNU 100 mg/m2 every 7 weeks for 1 year and every 10 weeks for the second year
Number of subjects: 346

Group type: COMPARATOR
Intervention: BCNU 200 mg/m2 every 7 weeks for 1 year and every 10 weeks for the second year
Number of subjects: 346
Study: 2426118

Group type: EXPERIMENTAL
Intervention: Substance P (SP) 65 micrograms
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 29361312

Group type: EXPERIMENTAL
Intervention: Continuous interpectoral block (CIPB) with 30mL of 0.5% ropivacaine and postoperative perfusion of ropivacaine 0.2% 5mL·h‐1; PCA bolus 5mL/30minutes for 24 hours
Number of subjects: 137

Group type: COMPARATOR
Intervention: Intravenous analgesia (IV) with fentanyl, metamizole, dexketoprofen, ondansetron, and postoperative perfusion of metamizole 4%, tramadol 0.2%, ondansetron 0.08% 2ml·h‐1; PCA bolus 2mL/20min for 24 hours
Number of subjects: 137
Study: 27219522

Group type: EXPERIMENTAL
Intervention: DE‐EBRT with bicalutamide 150 mg once daily for 5 months
Number of subjects: 252

Group type: COMPARATOR
Intervention: DE‐EBRT without hormone therapy
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: DE‐EBRT with bicalutamide
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Dose escalation to >75.6 Gy
Number of subjects: 252
Study: 25044219

Group type: EXPERIMENTAL
Intervention: Single oral 600 mg dose of linezolid (LZD)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Linezolid (LZD) administration timing
Number of subjects: 18
Study: 22950484

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 μg.kg(‐1) (Group 1)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 2 μg.kg(‐1) (Group 2)
Number of subjects: 116
Study: 20819564

Group type: EXPERIMENTAL
Intervention: Postcon-60s (3 cycles of 60-second balloon deflation and inflation)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Postcon-30s (3 cycles of 30-second balloon deflation and inflation)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Routine group (no intervention)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Postcon-60s
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Postcon-30s
Number of subjects: 75

Group type: COMPARATOR
Intervention: Routine group
Number of subjects: 75
Study: 18460987

Group type: EXPERIMENTAL
Intervention: Physical activity (measured using an accelerometer over 6 days)
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Fat and fat-free mass along with racial group
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity added to the regression model
Number of subjects: 1440

Group type: EXPERIMENTAL
Intervention: Racial group (Black girls)
Number of subjects: 1440
Study: 15971198

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (CBI), 10-contact, 20-week duration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study: 12052364

Group type: EXPERIMENTAL
Intervention: Mechanoemission chaos estimation in blood of gastric cancer patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with inflammation of gastric mucosa
Number of subjects: 0
Study: 10474783

Group type: EXPERIMENTAL
Intervention: Low fat diet (25% fat)
Number of subjects: 25

Group type: COMPARATOR
Intervention: High fat diet (40% fat)
Number of subjects: 25
Study: 8981710

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy with TPA
Number of subjects: 96